PF-03654746 + Placebo + Placebo + PF-03654746
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Tourette's Syndrome
Conditions
Tourette's Syndrome
Trial Timeline
Apr 1, 2012 → Apr 1, 2012
NCT ID
NCT01475383About PF-03654746 + Placebo + Placebo + PF-03654746
PF-03654746 + Placebo + Placebo + PF-03654746 is a phase 2 stage product being developed by Pfizer for Tourette's Syndrome. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01475383. Target conditions include Tourette's Syndrome.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01475383 | Phase 2 | Withdrawn |
Competing Products
2 competing products in Tourette's Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aripiprazole | Bristol Myers Squibb | Pre-clinical | 22 |
| Tetrabenazine MR + Placebo | Bausch Health | Phase 2 | 47 |